Previous Section
Drug Therapy
1. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
- Author
- Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF;
- Institution
- Department of Hematology, Second Affiliated Hospital, Hangzhou, Zhejiang Province 310009,China. zrxyk10@zju.edu.cn
- Journal
- Leuk Res. 2006 Jan;30(1):17-23. Epub 2005 Jul 14.
- Abstract URL
- Click here to view abstract
2. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
- Author
- Jabbour E; Kantarjian H; O'Brien S; Rios MB; Abruzzo L; Verstovsek S; Garcia-Manero G; Cortes J;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
- Journal
- Blood. 2006 Jan 15;107(2):480-2. Epub 2005 Sep 29.
- Abstract URL
- Click here to view abstract
3. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
- Author
- Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stephane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P;
- Institution
- Service d'Hematologie Clinique, Hopital Saint-Louis, Paris, France.
- Journal
- Leukemia. 2006 Mar;20(3):400-3.
- Abstract URL
- Click here to view abstract
4. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
- Author
- Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD;
- Institution
- Dana Farber Cancer Institute, Mayer 540, 44 Binney Street, Boston, MA 02115, USA.
- Journal
- Nat Rev Cancer. 2007 May;7(5):345-56.
- Abstract URL
- Click here to view abstract
5. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
- Author
- Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M;
- Institution
- Department of Hematology/Oncology L. and A. Seragnoli S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy. francesca.palandri@libero.it
- Journal
- J Clin Oncol. 2008 Jan 1;26(1):106-11.
- Abstract URL
- Click here to view abstract
6. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group.
- Author
- Sugita J; Tanaka J; Kurosawa M; Fukuhara T; Hashino S; Torimoto E; Koizumi K; Masauji N; Nishimura S; Koda K; Imamura M; Kasai M;
- Institution
- Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
- Journal
- Eur J Haematol. 2008 Feb;80(2):160-3. Epub 2007 Nov 17.
- Abstract URL
- Click here to view abstract
7. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
- Author
- Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D;
- Institution
- Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA.
- Journal
- J Clin Invest. 2007 Sep;117(9):2408-21.
- Abstract URL
- Click here to view abstract
8. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
- Author
- Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H;
- Institution
- Department of Leukemia, Unit 428, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
- Journal
- IDrugs. 2007 Jul;10(7):468-79.
- Abstract URL
- Click here to view abstract
9. Dasatinib.
- Author
- Shah NP;
- Institution
- Division of Hematology/Oncology, UCSF School of Medicine, San Francisco, California 94143, USA. nshah@medicine.ucsf.edu
- Journal
- Drugs Today (Barc). 2007 Jan;43(1):5-12.
- Abstract URL
- Click here to view abstract
10. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
- Author
- Quintas-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center. Houston, TX 77030, USA.
- Journal
- Leuk Lymphoma. 2007 Feb;48(2):283-9.
- Abstract URL
- Click here to view abstract
Next: Clinical Trials
